Premium
Gelatin Microspheres as Vehicle for Cardiac Progenitor Cells Delivery to the Myocardium
Author(s) -
Feyen Dries A. M.,
Gaetani Roberto,
Deddens Janine,
van Keulen Danielle,
van Opbergen Chantal,
Poldervaart Michelle,
Alblas Jacqueline,
Chamuleau Steven,
van Laake Linda W.,
Doevendans Pieter A.,
Sluijter Joost P. G.
Publication year - 2016
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201500861
Subject(s) - microcarrier , stem cell , gelatin , progenitor cell , cardiac function curve , cell , cell therapy , biomedical engineering , regenerative medicine , medicine , microbiology and biotechnology , chemistry , cardiology , biology , heart failure , biochemistry
Inadequate cell retention and survival in cardiac stem cell therapy seems to be reducing the therapeutic effect of the injected stem cells. In order to ameliorate their regenerative effects, various biomaterials are being investigated for their potential supportive properties. Here, gelatin microspheres (MS) are utilized as microcarriers to improve the delivery and therapeutic efficacy of cardiac progenitor cells (CPCs) in the ischemic myocardium. The gelatin MS, generated from a water‐in‐oil emulsion, are able to accommodate the attachment of CPCs, thereby maintaining their cardiogenic potential. In a mouse model of myocardial infarction, we demonstrated the ability of these microcarriers to substantially enhance cell engraftment in the myocardium as indicated by bioluminescent imaging and histological analysis. However, despite an observed tenfold increase in CPC numbers in the myocardium, echocardiography, and histology reveals that mice treated with MS‐CPCs show marginal improvement in cardiac function compared to CPCs only. Overall, a straightforward and translational approach is developed to increase the retention of stem cells in the ischemic myocardium. Even though the current biomaterial setup with CPCs as cell source does not translate into improved therapeutic action, coupling this developed technology with stem cell‐derived cardiomyocytes can lead to an effective remuscularization therapy.